EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market is segmented By Treatment (EGFR-TKI Inhibitors, Immunotherapy), By Stages of the Disease (Early-stage NSCLC, Metastatic NSCLC), By Therapy Approvals (First-line Treatments, Second-line Treatments), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa).The report offers the value (in USD billion) for the above-mentioned segments.
Competitive overview of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market
The major players operating in the EGFR non-small cell lung cancer (EGFR + NSCLC) market include AstraZeneca, Janssen Pharmaceuticals, Pfizer, Roche, Novartis, Cullinan Oncology, Bridge Biotherapeutics, ORIC Pharmaceuticals, BeiGene, Dizal Pharmaceuticals, Merck & Co., and Bristol-Myers Squibb.
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Leaders
- AstraZeneca
- Janssen Pharmaceuticals
- Pfizer
- Roche
- Novartis
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market - Competitive Rivalry, 2023
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market
(Dominated by major players)
(Highly competitive with lots of players.)